Fortress Biotech (FBIOP) Current Ratio: History & Chart

Fortress Biotech, Inc.(FBIOP)

Biotechnology · Bay Harbor Islands, FL

$17.50-0.60 (-3.31%)

Delayed quote: Oct 6, 2026, 10:44 AM EDT

About Fortress Biotech, Inc.

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for inflammatory lesions of rosacea; Exelderm, an antifungal cream and solution for topical use; Targadox, an oral doxycycline drug for therapy for severe acne; and Luxamend, a water-based emulsion to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, sunburns, and radiation dermatitis. It also develops intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for Menkes disease; UNLOXCYT for metastatic cutaneous squamous cell carcinoma; Olafertinib for EGFR mutation-positive NSCLC; CAEL-101, a monoclonal antibody for amyloid light chain amyloidosis; and Triplex, a cytomegalovirus vaccine. In addition, the company's early-stage product candidates include Dotinurad for gout; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma and anaplastic astrocytoma; MB-106 for B-cell non-hodgkin lymphoma; AJ201, an androgen receptor degradation enhancer; and BAER-101, a positive allosteric modulator. Further, its preclinical product candidates comprise AAV-ATP7A and AVTS-001 gene therapies; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Bay Harbor Islands, FL

78 employees

www.fortressbiotech.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Lindsay A. Rosenwald

View full financials

FBIOP Current Ratio Metrics

CURRENT RATIO

3.96

CURRENT RATIO AVG TTM

2.68

CURRENT RATIO AVG 3Y

1.65

CURRENT RATIO AVG 5Y

2.22

CURRENT RATIO AVG 10Y

2.66

CURRENT RATIO AVG 15Y

4.34

CURRENT RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

+47.52%

CURRENT VS 3Y AVG

+140.55%

CURRENT VS 5Y AVG

+78.61%

CURRENT VS 10Y AVG

+48.84%

CURRENT VS 15Y AVG

-8.75%

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

3.40

median of 616 covered companies

CURRENT VS SECTOR MEDIAN

+16.60%

vs the sector median at left

NAME	MARKET CAP	CURRENT RATIO	TTM	3Y	5Y
Fortress Biotech, Inc. (FBIOP)	$137.77M	3.96	2.68	1.65	2.22
AirSculpt Technologies, Inc. (AIRS)vs ›	$139.33M	0.79	0.57	0.67	0.95
Alpha Cognition Inc (ACOG)vs ›	$138.69M	9.03	11.82	6.24	5.64
KORU Medical Systems, Inc. (KRMD)vs ›	$136.65M	2.72	2.55	3.48	5.33
Nyxoah S.A. (NYXH)vs ›	$140.10M	2.38	2.90	4.31	7.34
LifeMD, Inc. (LFMD)vs ›	$135.12M	0.90	1.03	0.91	1.08
Freenome, Inc. (FRNM)vs ›	$132.35M	N/A	N/A	N/A	N/A
Immuneering Corporation (IMRX)vs ›	$143.76M	19.47	11.39	11.91	15.23
Korsana Biosciences, Inc. (KRSA)vs ›	$145.59M	0.82	5.49	4.19	4.20
Acumen Pharmaceuticals, Inc. (ABOS)vs ›	$146.58M	2.47	5.27	13.16	16.37

NAME

MARKET CAP

CURRENT RATIO

TTM

Fortress Biotech, Inc. (FBIOP)

$137.77M

3.96

2.68

1.65

2.22

AirSculpt Technologies, Inc. (AIRS)vs ›

$139.33M

0.79

0.57

0.67

0.95

Alpha Cognition Inc (ACOG)vs ›

$138.69M

9.03

11.82

6.24

5.64

KORU Medical Systems, Inc. (KRMD)vs ›

$136.65M

2.72

2.55

3.48

5.33

Nyxoah S.A. (NYXH)vs ›

$140.10M

2.38

2.90

4.31

7.34

LifeMD, Inc. (LFMD)vs ›

$135.12M

0.90

1.03

0.91

1.08

Freenome, Inc. (FRNM)vs ›

$132.35M

N/A

Immuneering Corporation (IMRX)vs ›

$143.76M

19.47

11.39

11.91

15.23

Korsana Biosciences, Inc. (KRSA)vs ›

$145.59M

0.82

5.49

4.19

4.20

Acumen Pharmaceuticals, Inc. (ABOS)vs ›

$146.58M

2.47

5.27

13.16

16.37

Current Ratio FAQ

What is the current ratio for Fortress Biotech, Inc. (FBIOP)?

The current ratio for FBIOP stock is 3.96.

Is Fortress Biotech, Inc.'s current ratio high or low?

The current ratio of 3.96 is 79% above its 5-year average of 2.22, near the high end of its 5-year range (0.99–4.54).

What is the TTM average current ratio for Fortress Biotech, Inc. (FBIOP)?

The TTM average current ratio for FBIOP stock is 2.68.

What is the 3Y average current ratio for Fortress Biotech, Inc. (FBIOP)?

The 3Y average current ratio for FBIOP stock is 1.65.

What is the 5Y average current ratio for Fortress Biotech, Inc. (FBIOP)?

The 5Y average current ratio for FBIOP stock is 2.22.

What is the 10Y average current ratio for Fortress Biotech, Inc. (FBIOP)?

The 10Y average current ratio for FBIOP stock is 2.66.

What is the 15Y average current ratio for Fortress Biotech, Inc. (FBIOP)?

The 15Y average current ratio for FBIOP stock is 4.34.

DATE	CURRENT RATIO
2026-06-30	3.96
2026-03-31	2.86
2025-12-31	2.49
2025-09-30	2.19
2025-06-30	1.92
2025-03-31	1.72
2024-12-31	1.27
2024-09-30	1.23
2024-06-30	1.37
2024-03-31	1.33
2023-12-31	1.38
2023-09-30	1.00
2023-06-30	0.99
2023-03-31	1.56
2022-12-31	1.80
2022-09-30	2.43
2022-06-30	2.85
2022-03-31	3.31
2021-12-31	3.43
2021-09-30	2.92
2021-06-30	4.54
2021-03-31	5.91
2020-12-31	5.14
2020-09-30	6.38
2020-06-30	3.51
2020-03-31	3.07
2019-12-31	3.43
2019-09-30	3.55
2019-06-30	4.49
2019-03-31	2.79
2018-12-31	2.00
2018-09-30	2.25
2018-06-30	2.76
2018-03-31	2.52
2017-12-31	2.72
2017-09-30	2.69
2017-06-30	3.56
2017-03-31	2.88
2016-12-31	1.94
2016-09-30	2.55
2016-06-30	5.34
2016-03-31	7.78
2015-12-31	9.43
2015-09-30	7.88
2015-06-30	12.42
2015-03-31	11.74
2014-12-31	17.28
2014-09-30	20.26
2014-06-30	22.25
2014-03-31	18.57
2013-12-31	8.92
2013-09-30	11.05
2013-06-30	7.61
2013-03-31	7.31
2012-12-31	7.91
2012-09-30	10.75
2012-06-30	9.80
2012-03-31	4.70
2011-12-31	6.69
2011-09-30	7.26
2011-06-30	0.00
2011-03-31	0.00
2010-12-31	0.00
2010-09-30	0.00

DATE

CURRENT RATIO

2026-06-30

3.96

2026-03-31

2.86

2025-12-31

2.49

2025-09-30

2.19

2025-06-30

1.92

2025-03-31

1.72

2024-12-31

1.27

2024-09-30

1.23

2024-06-30

1.37

2024-03-31

1.33

2023-12-31

1.38

2023-09-30

1.00

2023-06-30

0.99

2023-03-31

1.56

2022-12-31

1.80

2022-09-30

2.43

2022-06-30

2.85

2022-03-31

3.31

2021-12-31

3.43

2021-09-30

2.92

2021-06-30

4.54

2021-03-31

5.91

2020-12-31

5.14

2020-09-30

6.38

2020-06-30

3.51

2020-03-31

3.07

2019-12-31

3.43

2019-09-30

3.55

2019-06-30

4.49

2019-03-31

2.79

2018-12-31

2.00

2018-09-30

2.25

2018-06-30

2.76

2018-03-31

2.52

2017-12-31

2.72

2017-09-30

2.69

2017-06-30

3.56

2017-03-31

2.88

2016-12-31

1.94

2016-09-30

2.55

2016-06-30

5.34

2016-03-31

7.78

2015-12-31

9.43

2015-09-30

7.88

2015-06-30

12.42

2015-03-31

11.74

2014-12-31

17.28

2014-09-30

20.26

2014-06-30

22.25

2014-03-31

18.57

2013-12-31

8.92

2013-09-30

11.05

2013-06-30

7.61

2013-03-31

7.31

2012-12-31

7.91

2012-09-30

10.75

2012-06-30

9.80

2012-03-31

4.70

2011-12-31

6.69

2011-09-30

7.26

2011-06-30

0.00

2011-03-31

0.00

2010-12-31

0.00

2010-09-30

0.00

Current Ratio: 3.96

FBIOP Current Ratio

FBIOP Average Current Ratio Chart

FBIOP Current vs Average Current Ratio Chart

FBIOP Current Ratio Metrics

FBIOP Competitors' Current Ratio

Liquidity Analysis

Current Ratio Formula & Definition

Current Ratio FAQ

FBIOP Current Ratio History

Related Metrics